However, the higher percentage (20%) of NSCLC patients with progressive disease after 6 months of immunotherapy treatment with or without chemotherapy was found in patients with positive KRAS mutational status with PDL1 expression < 49%. This evidence concerns the gene KRAS and non-small cell lung carcinoma.